1. Entwodiksyon
Huperzine A poud se yon inhibitor asetilkolinesteraz trè selektif. Li ka antre nan nève santral la
sistèm ak egzèse efè li. Kono Chem Co, Ltd ka bay pwodwi sa a ak pite diferan, youn ki pi popilè a se 1 pousan pite, epi tou 5 pousan ak 98 pousan ki disponib.
2. Fonksyon prensipal yo
2.1.Huperzine A powder can help treat Alzheimer's disease and improve memory loss in middle-aged and elderly people, and improve associative recall function;for memory loss caused by overuse of the brain to improve learning and work efficiency. A multicenter, randomized, double-blind, controlled study, 202 AD patients from 15 centers across the country were randomized to receive huperzine A or placebo for 12 weeks. Huperzine A group (400ug/d) 100 cases, placebo group 102 cases, assessment every 6 weeks, the results show that Huperzine A can significantly improve cognitive function, behavior and mood disorders, activities of daily living in AD patients capability and overall functionality, with good security.
2.2.Amelyore fonksyon mantal apre operasyon nan pasyan granmoun aje.
De etid kontwole owaza sou efè preoperativ Huperzine A sou fonksyon mantal apre operasyon nan pasyan granmoun aje. Nan etid sa a, 80 ak 100 pasyan granmoun aje ki te ale nan sibi operasyon nan vant yo te chwazi, ak rezilta yo te montre ke Huperzine A ta ka diminye ensidans la nan malfonksyònman mantal apre operasyon (POCD) nan pasyan granmoun aje chirijikal, epi redwi pèsepsyon an nan anestezi jeneral pou granmoun aje yo. enfliyans konesans.
2.3.Trete myasthenia gravis
Myasthenia gravis (MG) se yon maladi otoiminitè ki enplike reseptè asetilkolin (AchR) sou manbràn postsynaptic la nan junction neromiskilè a, epi li karakterize pa rekiperasyon pasyèl apre administrasyon dwòg anticholinesterase. Huperzine A se yon inibitè kolinesteraz ki pisan ak revèsib ak gwo aktivite imite kolin
2.4.Amelyore dòmi ak reveye ritm sik, amelyore kalite dòmi, ak trete lensomni kwonik.
3. Aplikasyon
Huperzine A Powder yo itilize nan pwodwi swen sante ak endistri pharmaceutique.
4. Flux Chart
5. Estanda Kalite
Dapre Enterprise Standard
Atik | Espesifikasyon | Rezilta yo |
Aparans | Blan amann poud | Blan amann poud |
Odè & gou | Karakteristik | Karakteristik |
Gwosè patikil | 100 pousan pase 80 may | Konfòme |
Pèdi sou siye | Mwens pase oswa egal a 5.0 pousan | 3.9 pousan |
Metal lou | Mwens pase oswa egal a 1 ppm | <> |
Pb | Mwens pase oswa egal a 1 ppm | <> |
Kòm | Mwens pase oswa egal a 1 ppm | <> |
Hg | Mwens pase oswa egal a 0.1ppm | <> |
Cd | Mwens pase oswa egal a 0.5ppm | <> |
Sann kontni | Mwens pase oswa egal a 5.0 pousan | 0.3 pousan |
Konte Plak Total | Mwens pase oswa egal a 1000cfu/g | Konfòme |
Total ledven ak mwazi | Mwens pase oswa egal a 100cfu/g | Konfòme |
E.Coli. | Negatif | Pa detekte |
Salmonèl | Negatif | Pa detekte |
B1 (aflatoksin) | Mwens pase oswa egal a 5.0ug/kg | <5.0ug> |
Rezidans solvants | Mwens pase oswa egal a 0.5 pousan | <> |
BHC | Mwens pase oswa egal a 0.10mg/kg | <0.10mg> |
DDT | Mwens pase oswa egal a 0.10mg/kg | <0.10mg> |
PCNB | Mwens pase oswa egal a 0.10mg/kg | <0.10mg> |
Aldrin | Mwens pase oswa egal a 0.02mg/kg | <0.02mg> |
Esè (HPLC) | Pi gran pase oswa egal a 1 pousan | 1.02 pousan |
6. Metòd analiz
MOA disponib sou demann
7. Referans Spectrum
8. Estabilite ak Sekirite
Estabilite:
Ki estab nan kondisyon apwopriye (tanperati chanm). Fèy Done Estabilite disponib sou demann ou an.
Sekirite:
Li se ki pa mutagen, inofensif ak ki pa irratant, pa gen okenn lage prostaglandin enflamatwa, pa gen okenn ogmantasyon nan liz selilè, pa gen okenn efè sou sitokin. Li san danje pou swen pou po.
9. Kòmantè Kliyan yo
10. Sètifika nou an
11.Kliyan nou yo
12.Egzibisyon
Baj popilè: huperzine yon poud 102518-79-6, manifaktirè, founisè, faktori, wholesale, achte, pri, pi bon, esansyèl, pou vann
